Postexposure trial of a human diploid cell strain rabies vaccine.
A human diploid cell strain vaccine (HDCV) was evaluated in 90 persons treated after exposure to rabies, 21 of whom were bitten by proven rabid animals. Intramuscular doses of HDCV were given on days 0, 3, 7, 14, and 28, and human rabies immune globulin (HRIG) was given on day 0. Antibody to rabies virus was tested for by the rapid fluorescent focus inhibition test; adverse reactions were assessed from physician's forms. All 87 persons tested developed titers of greater than or equal to 0.5 international units (IU)/ml, with a maximum geometric mean titer of 15.0 IU/ml on day 42. One year after vaccination, all 33 persons tested had antibody to rabies virus. After one or more doses of vaccine, mild local or systemic reactions were reported in 19.0% and 21.4% of persons, respectively. No serious reactions occurred. The results show that this HDCV (plus HRIG) was safe and effective in eliciting antibody in postexposure prophylaxis of rabies. When it becomes available, it is recommended over the present treatment regimen.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002415:Cats; D002648:Child; D002675:Child, Preschool; D002685:Chiroptera; D004285:Dogs; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012889:Mephitidae; D008875:Middle Aged; D011819:Rabies Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D011821:Raccoons; D013997:Time Factors
D000914:Antibodies, Viral; D011819:Rabies Vaccines